Entity

Time filter

Source Type


Li X.,The Affiliated Hospital of Jining Medical College
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery | Year: 2012

To investigate the expression of breast cancer metastasis suppressor 1 (BRMS1) gene protein and the expression of BRMS1 gene promotor area methylation in supraglottic cancer and to evaluate its clinical significance. The expression of BRMS1 protein and BRMS1 gene promotor area methylation were examined by using Western blotting method and methylation-specific polymerase chain reaction(MSP) method in 70 cases of supraglottic cancer tissues and 60 cases of their surrounding laryngeal normal mucosa tissues (LNT) and 44 cases of cervical lymph node metastasis of supraglottic cancer. Western blot results indicate that BRMS1 protein expression is declined expression level in supraglottic cancer tissue than the expression of BRMS1 protein in LNT of supraglottic cancer. Compared with para carcinoma normal laryngeal mucous tissue, BRMS1 gene protein in supraglottic cancer tissue primary lesion decreased obviously, and it is decreased more obviously in cervical lymph node metastasis lesion, the discrepancy is notable (P < 0.05). MSP results indicate BRMS1 gene promotor methylation is coordinated with its down-expression in supraglottic cancer tissue. BRMS1 promotor area methylation analysis reveal that there were 34 patients with methylation in 70 patients' supraglottic cancer tumor primary lesion, hold 48.6% (34/70); 32 patients have methylation in 44 patients' cervical metastasis lymph node tissue, hold 72.7% (32/44); however, there is no methylation in 60 para carcinoma tissue (r(s) = 0.66, P < 0.05). The expression of BRMS1 protein in supraglottic cancer is significantly decreased. It had correlation with clinical stage and pathologic differentiation and cervical lymph node metastasis of supraglottic cancer. BRMS1 gene promotor methylation is related with down-expression of BRMS1 gene protein of supraglottic cancer. Maybe BRMS1 gene promotor methylation is one of the reasons of its down-expression. Source


Huang L.,The Affiliated Hospital of Jining Medical College | Zhang F.-J.,Capital Medical University
International Journal of Ophthalmology | Year: 2011

AIM: To evaluate the efficacy and safety of Pranoprofen eye drops in relieving reactions of postoperative inflammation of Nd:YAG laser to treat the disease of the anterior segment of the eye. METHODS: Totally 60 cases (60 eyes) with angle-closed glaucoma were performed laser peripheral iridotomy(LPI) and laser capsulotomy, then were randomly divided into two groups, experimental group and control group, 30 cases (30 eyes) of each group. Pranoprofen and TobraDex eye drops, four times each day, were administered in experimental and control group respectively. All patients had been observed for 7 days. Ocular pain, photophobia, epiphora, conjunctival congestion, keratitis, aqueous humor flare were observed and recorded to calculate a comprehensive score to assess the curative effects. RESULTS; There was no significant difference in comprehensive score between the two groups at 1 day, 3, 7 days postoperatively (P>0.05). CONCLUSION: Pranoprofen eye drops have excellent efficacy and safety to control the inflammation after laser peripheral iridotomy and laser capsulotomy, it can decrease the danger of high intraocular pressure due to corticosteroid. Source


Song Q.,The Affiliated Hospital of Jining Medical College
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban | Year: 2010

To investigate the possible mechanism of action of tripterygium glycosides (TG) for treatment of Behcet's disease (BD) through observing its effect on serum levels of interleukin-1beta (IL-1beta), interleukin-2 (IL-2), tumor necrosis factor alpha (TNF-alpha) and interferon-gamma (IFN-gamma). Thirty primarily treated BD patients (BD group) were treated with TG 30 mg/d orally for 3 months, and a control group consisting of 30 healthy persons was set up. Serum levels of IL-1beta, IL-2, TNF-alpha and IFN-gamma were detected by radio-immunosorbent assay (RIA) before and after treatment respectively. And the outcomes were analyzed in combining with the clinical status of patients as well as related indices as erythrocyte sedimentation (ESR) and C-reactive protein (CRP). Serum levels of IL-1beta, TNF-alpha, IFN-gamma in the BD group were evidently higher (P < 0.05) than those in the control group, they all lowered significantly after 3-month TG treatment, from 10.72 +/- 1.84 microg/L, 6.64 +/- 1.05 microg/L and 8.93 +/- 1.23 microg/L to 5.71 +/- 1.04 microg/L, 4.27 +/- 0.76 microg/L and 3.44 +/- 0.72 microg/L, respectively (P < 0.05), while level of IL-2 in the BD group was insignificantly different before treatment to that in the control (though showed an increasing trend) and was unchanged after treatment (P > 0.05). TG treatment showed the effectiveness of markedly effective in 10, effective in 16 and ineffective in 4 BD patients, with the total effective rate of 86.6%. Besides, ESR and CRP levels were evidently decreased in BD patients after treatment (P < 0.05). TG may treat BD by way of regulating the levels of IL-1beta,TNF-alpha and IFN-gamma. Source


Gan L.J.,The Affiliated Hospital of Jining Medical College
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban | Year: 2010

To evaluate the effect and safety of Xuesaitong (XST, a Panax Notoginseng extract preparation) via intracoronary injection for treating post-PCI slow-reflow phenomenon in patients with ST-segment elevation myocardial infarction (STEMI) and its impact on patients' prognosis. Thirty-nine STEMI patients who suffered from post-PCI slow-reflow after received percutaneous transluminal coronary angioplasty or stenting were assigned to two groups, 20 patients in the treated group and 19 in the control group. Intracoronary administering of 10 mL (0.5 mg) tirofiban and 400 mg XST were given to the treated group through guiding catheter, and followed with 36 h continuous intravenous dripping of tirofiban 10 mL/h and 400 mg XST in 250 mL of saline for dripping, while to the control group, the same intracoronary administering and intravenous dripping of tirofiban but without XST was given. The treatment was implemented for two days. Patients' coronary flow was assessed by the TIMI frame count method (TFC) at 1 min, 5 min and 10 min after injection; and the changes of ST-segment in 2 h, and incidence of bleeding in 48 h after medication were recorded. All patients were followed-up for 6 months to observe the incidence of cardiovascular events. Before the medication, the TIMI flow grade and the TFC in the treated group and the control group showed insignificantly statistical difference between groups (P > 0.05). After medication, 11 patients (55%) in the treated group and 8 patients (42%) in the control group with their blood flow reaching TIMI grade 3; the TFC decreased at 1, 5 and 10 min to 57.6 +/- 12.6, 46.1 +/- 9.3, 49.8 +/- 10.9 in the treated group and to 69.3 +/- 16.1, 61.2 +/- 15.3, 63.7 +/- 18.3 in the control group; and the 2 h ST segment fallback in them was 1.85 +/- 0.31 mm and 1.40 +/- 0.21 mm respectively, showing that the coronary blood flow in both groups were improved significantly after medication but the improvement in the former was better than in the latter group (P < 0.05). No case of death occurred in the hospitalization period. Results of 6-month follow-up study showed that the incidence of major adverse cardiac events, including angina pectoris, myocardial infarction, heart failure and cardiac death, was 33% in treated group and 44% in the control group, showing insignificant difference between groups (P > 0.05). Concomitant coronary injection with tirofiban and XST is more effective than that with tirofiban alone in improving the coronary blood flow and shows no increasing on the incidence of hemorrhagic complication. Source


Pang T.Z.,The Affiliated Hospital of Jining Medical College
Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery | Year: 2012

To explore and evaluate the application of epiglottis with sternohyoid muscle in the surgery for laryngeal cancer. Two fifty patients with laryngeal cancer were treated by partial laryngectomy and the laryngeal defects were reconstructed by epiglottic flap and sternohyoid muscle fascia flap. The staging of tumors: T2N0M0 23 cases, T3N1M0 14 cases, T3N2M0 13 cases. All of them received post radical radiotherapy with average 60 Gy. The patients were followed up for 3 to 5 years. Thirty patients underwent neck dissection. The three and five years survival rates were 90% and 80% respectively. The total cases eat breath pronounced well. The decannulation rate was 96%. After partial laryngectomy in laryngeal cancer epiglottic flap and sternohyoid muscle fascia flap were performed reconstruction of laryngeal function. Source

Discover hidden collaborations